SpringWorks Therapeutics Share Holder Equity 2019-2022 | SWTX
SpringWorks Therapeutics share holder equity from 2019 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
SpringWorks Therapeutics Annual Share Holder Equity
(Millions of US $) |
| 2021 |
$422 |
| 2020 |
$557 |
| 2019 |
$322 |
| 2018 |
$44 |
SpringWorks Therapeutics Quarterly Share Holder Equity
(Millions of US $) |
| 2022-03-31 |
$377 |
| 2021-12-31 |
$422 |
| 2021-09-30 |
$467 |
| 2021-06-30 |
$497 |
| 2021-03-31 |
$535 |
| 2020-12-31 |
$557 |
| 2020-09-30 |
$273 |
| 2020-06-30 |
$291 |
| 2020-03-31 |
$308 |
| 2019-12-31 |
$322 |
| 2019-09-30 |
$337 |
| 2019-06-30 |
$0 |
| 2019-03-31 |
$0 |
| 2018-12-31 |
|
| 2018-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.838B |
$0.035B |
|
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
|
